A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Items 501–600 of 602
Dennis, R., Rojas, M. X., Rondon, M., Parada, L. A., & Villar, J. C. (2015) · Acta Médica Colombiana · doi:10.36104/amc.2015.563 · Cited by 2
Tarlovskaya, E. I., Нечаева, Г. И., Malchikova, S. V., & Semenkin, А. А. (2015) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2015-4-29-37 · Cited by 2
Salado-Font, S. M., Lopez-Munoz, F. J., Povedano-Montero, F. J., & Quesada, F. L. (2017) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2017.01.011 · Cited by 2
Salado-Font, S. M., López-Muñoz, F., Povedano-Montero, F. J., & Quesada, F. L. (2017) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2017.05.005 · Cited by 2
Statins for preventing cardiovascular disease
Moore, T., Bartlett, C., Burke, M., Smith, G. D., & Ebrahim, S. B. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub2 · Cited by 2
Review: Statins reduce mortality and major vascular events in patients with no history of CV disease
Elley, C. R. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-2-201307160-02002 · Cited by 2
Briggs, A. D. M. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-o885njxnx · Cited by 2
Ribeiro, R. A. (2011) · Lume (Universidade Federal do Rio Grande do Sul) · Cited by 2
Mind the Gap! - Geographic transferability of economic evaluation in health
Boehler, C. E. H. (2013) · Brunel University Research Archive (BURA) (Brunel University London) · Cited by 2
Gillies, C. (2007) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Lin, Y., Wang, C., Huang, X., Zhou, X., Zhou, Y., Mao, F., Guan, J., Song, Y. M., Zhong, Y., Xu, Y., et al. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05207-x · Cited by 1
Franklin, M., Fotheringham, J., Taylor, R. S., Powell, P. A., Retat, L., Chen, J., Sánchez, J. J. G., Gamble, A., & Carter, P. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01625-0 · Cited by 1
“Smith et al. [16], Sharp et al. [15] and Kandzari et al. [23] reported the same utility values for MI (0.76) [61–63], post-MI (0.88) [64–66] and stroke (0.63) [63, 64, 67], despite using different sources.”
InfluentialRibichini, F. L., Ryschon, A. M., Tacconi, E., Weber, S. A., Taddei, S., & Pietzsch, J. B. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00810-8 · Cited by 1
Modern cardiovascular risk management in clinical practice
Volpe, M., Calvieri, C., & Alonzo, A. (2009) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2009.01.005 · Cited by 1
Bejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Angiología · doi:10.1016/j.angio.2014.09.016 · Cited by 1
Estatinas, uso racional en el tratamiento de la dislipoproteinemia
Ferrer, J. I. (2009) · Revista cubana de medicina general integral · Cited by 1
Suh, S., Jung, C. H., Hong, S. J., Kim, J., Song, B. J., Sohn, H. S., & Choi, S. H. (2016) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2016.5.1.61 · Cited by 1
“임이 밝혀져 있다.(4,5) 이런 연구결과들을 바탕으로 최근 American College of Cardiology-American Heart Association (ACC- AHA)에서 발표된 심혈관질환의 예방을 위한”
Crossan, C., Dehbi, H., Williams, H., Poulter, N. R., Rodgers, A., Jan, S., Thom, S., & Lord, J. (2018) · BMJ Open · doi:10.1136/bmjopen-2016-013063 · Cited by 1
Does aerobic exercise have a beneficial effect on plasma lipid profile in young soccer players
Nowak, R., Kostrzewa‐Nowak, D., & Еider, J. (2015) · Wielkopolska Digital Library · Cited by 1
Choe, S., Shinn, J., Kim, H., & Kim, J. H. (2020) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2020.2.e14 · Cited by 1
Xia, Y., Leung, K. S. M., & Zhao, J. (2026) · npj Cardiovascular Health · doi:10.1038/s44325-026-00121-w · Cited by 1
Lääkkeet sydäninfarktin hoidossa : Statiinihoidon hyödyt ja haitat
Nguyen, L., Jurvanen, H., Häkkinen, U., Sund, R., Syvänne, M., & Tierala, I. (2016) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 1
KEY PROVISIONS OF THE NEW (2016) EUROPEAN GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIAS AND COMMENTS
Bubnova, M. G. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-19-12-20 · Cited by 1
Preservación de la fertilidad femenina
Comtet, M., Bénard, J., & Grynberg, M. (2017) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(16)82403-0 · Cited by 1
Nguyen, L., Häkkinen, U., & Jurvanen, H. (2018) · Nordic Journal of Health Economics · doi:10.5617/njhe.4538 · Cited by 1
“10 000 and GBP 17 000 for patients aged 45–85 (Ward et al., 2007).”
BackgroundResultInfluentialHeathcote, L., Pollard, D. J., Brennan, A., Davies, M. J., Eborall, H., Edwardson, C. L., Gillett, M., Gray, L. J., Griffin, S. J., Hardeman, W., et al. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003516 · Cited by 1
“27 Beta regression was chosen because it made it possible to generate variability in HbA1c values among individuals with identical baseline characteristics.”
MethodInfluentialWard, S. E., Ara, R., Pandor, A., & Hall, A. S. (2008) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Self-citationPettersson, B. (2012) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Is Statin Use Really Associated With Efficacy of Rituximab?
Asai, H., Yokoyama, M., Terui, Y., Ennishi, D., Takeuchi, K., & Hatake, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8654 · Cited by 1
Katz, I. J. (2011) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg) · Cited by 1
Low fat diets for acquired hypercholesterolemia
Smart, N. A., Marshall, B. J., Daley, M., Ebenstreit, C., Boulos, E., & Macaulay, L. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007957 · Cited by 1
Campbell, H., Chappell, L. C., McManus, R., Tucker, K., & Arias, O. R. (2024) · Oxford University Research Archive (ORA) (University of Oxford) · Cited by 1
Hartley, L. (2012) · University of Birmingham Institutional Research Archive (University of Birmingham)
The economic evaluations of interventions for heart diseases
Yao, G. (2010) · University of Birmingham Institutional Research Archive (University of Birmingham)
What is the optimal model of service delivery in Transient Ischaemic Attack
Kandiyali, R. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Simvastatin: between clinics and health economics
Costa, F. V., & Zaniolo, O. (2007) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v8i1.253
Incorporation of economic evidence in the Dutch guideline ‘cardiovascular risk management’
Tan, S. S., Rutten, F., & Roijen, L. H. (2010) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01481.x
“Lifetime therapy with simvastatin is therefore slightly more cost-effective than lifetime therapy with pravastatin [18,23].”
BackgroundInfluentialIdentification and Treatment of Women with Familial Hypercholesterolemia
Robinson, J. G. (2012) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-012-0231-7
“In general, statins used for secondary prevention are about twice as cost-effective as when used for primary prevention [26].”
BackgroundPark, H., & Rascati, K. L. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.12.009
Faut-il modifier nos indications suite aux conclusions de l'étude EVAR2 ?
Sobocinski, J., Maurel, B., Delsart, P., D’Elia, P., Guillou, M., Maioli, F., Perot, C., Bianchini, A., Azzaoui, R., Mounier‐Véhier, C., et al. (2011) · Annales de Chirurgie Vasculaire · doi:10.1016/j.acvfr.2012.06.001
Statins as primary prevention in patients without dislipidaemia
Chalmers, L., & Bereznicki, L. (2009) · UTAS Research Repository
Westover, M. B., Eiseman, N. A., & Bianchi, M. T. (2012) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.02.011
“For some diseases, it is appropriate to include in the model a decrement in QOL at the time of transition, as when the nonlethal event may leave the patient disabled [11].”
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Bowater, R. J., Hartley, L., & Lilford, R. J. (2015)
A REVIEW ON ROLE OF STATINS IN HYPERLIPIDEMIA PATIENTS
Nagar, A. (2014)
The Regression Discontinuity Design In Epidemiology: An Application To Statins
Baio, G., & Geneletti, S. (2013)
Touré, P. S., Léye, Y. M., Diop, M., Leye, A., Touré, S., Mohamed, Y., Maguette, M., Diop, M., Mourtalla, M., & Ka (2013)
Tamraz, B. (2011) · eScholarship (California Digital Library)
Pf, V. G., Tariq, L., Hh, H.-V. R., & van den Berg, M. (2009) · Rivm Repository (Netherlands National Institute for Public Health and the Environment)
Cancer, N., Ara, R., Duarte, A., Harnan, S., Palmer, S., Sculpher, M., & Brazier, J. E. (2015)
Self-citationBedeutung der Syntrophin-Isoformen alpha und beta2 für den hepatischen Lipidstoffwechsel
Hebel, T. (2016) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.33801
Mehta, D., Hansen, G. L., Østigård, H., Bjørnstad, M., Pettersen, I., Salvesen, R. M., & Rollefstad, S. (2012)
Post-mastectomy Adjuvant Radiotherapy (PMRT)
Görken, İ. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-26012-9_10
Arterial disease and its management
Chalmers, R. T. A. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511736537.002
The Regression Discontinuity Design in Epidemiology
Petersen, I., Ricciardi, F., Nazareth, I., Baio, G., Geneletti, S., & O’Keeffe, A. G. (2016) · UCL Discovery (University College London)
García-Gordillo, M., & Ángel, M. (2017) · Institutional Repository University of Extremadura (University of Extremadura)
National evaluation of the NHS Health Check programme
Chang, K. (2016) · Spiral (Imperial College London) · doi:10.25560/48467
Peñaloza-Ramos, M. C. (2017) · University of Birmingham Institutional Research Archive (University of Birmingham)
Boogen, E. M. (2008) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-16272
Almaghrabi, A. T., Alghamdi, W. M., Almuyidi, S. M., & Abuzaid, H. H. (2018) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2018.16936
A Vietnamese woman with a 2-week history of cough
Natali, D., Pham, H. T., & Nguyen, H. T. (2019) · Breathe · doi:10.1183/20734735.0256-2018
Zechmeister, I., Stollenwerk, B., Ara, R., & Ward, S. (2008) · Repository of the Ludwig Boltzmann Institute of Health Technology Assessment (Ludwig Boltzmann Institute of Health Technology Assessment)
Self-citationGc, V. S. (2018) · UEA Digital Repository (University of East Anglia)
Lipoproteina (a) e risco vascular
Brandão, J. A. M. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/23md-xf81
Montani, T. (2011) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-164020
Amirsadri, M., Hajhashemi, V., & Asemi, A. S. (2021) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_21_22
“016 [16] Subsequent years of nonfatal MI to fatal MI 0.”
BackgroundAzar, F. E. F., Aboutorabi, A., Afrouzi, M., Hajahmadi, M., & Karpasand, S. (2021) · Journal of Education and Health Promotion · doi:10.4103/jehp.jehp_1590_20
The Role of Liver X Receptors in Reverse Cholesterol Transport and Atherosclerosis
Breevoort, S. R. (2014) · doi:10.18130/v3925p
Jacbs, R. S. W., & BILLING., G. C. (2018)
The Mevalonate Pathway: A Potential Therapeutic Target for JAK2-driven Myeloproliferative Neoplasms
Griner, L. N. (2013) · Digital Commons - University of South Florida (University of South Florida)
Tsioufis, C. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735765988.793578597
FTIR ANALYSIS OF PLASMA COQ 10 IN ATORVOSTATIN TREATED HYPERLIPIDAEMIA PATIENTS WITH MYOPATHY
Subramaniam, S. (2022) · INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT · doi:10.55041/ijsrem16101
Tsuji, R. L. G. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-03102022-141758
The inhibitory effect of anthocyanins-rich Thai berries extracts on lipid digestion and absorption
Chamnansilpa, N. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.255
CADTH (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.872
Ravangard, R., Ghanbari, M., Attar, A., & Jafari, A. (2024) · Health Science Reports · doi:10.1002/hsr2.2240
Les statines en Belgique: évolutions de l’utilisation et impact des politiques de remboursement
Roberfroid, D., Dubois, C., Vrijens, F., Camberlin, C., & Farfan-Portet, M.-I. (2010) · doi:10.57598/r141b
Dewi, P. E. N., Chairani, F., & Himawan, W. (2025) · JURNAL ILMU KEFARMASIAN INDONESIA · doi:10.35814/jifi.v23i1.1604
“A literature review from the UK reported about the cost-effectiveness of statins as a coronary heart disease prevention will decrease due to the ages range 45-85 which is indicated by the inclining of ICER [22].”
Nutritional derailments and management of nephrotic syndrome
Eduful, E., & Boima, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33090-2.00016-3
Lamu, A. N., Jbaily, A., Verguet, S., Robberstad, B., & Norheim, O. F. (2020) · Figshare · doi:10.6084/m9.figshare.13346730
Estrategia de diabetes de les Illes Balears 2011-2015
Bestard Juan, M., Irigoyen, E. C., Jaume, M. C., Jäger, E. C., Riera, E. J. C., Marcet, M. C., Comendeiro Maaloe, M., Culebras, J. F., Gómez, L. A., Vidal, M. L., et al. (2011) · Hispana
Liikunnan vaikutus veren lipidiarvoihin
Lemmetty, S. (2018) · UTUPub (University of Turku)
Smith, R. (2023) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Alimam, S. (2020) · UEF eRepo (University of Eastern Finland)
Rahim, A., Chong, H. Y., Knight, L., Willis, S., Kiseleva, M., Dale, M., Grove-Hills, A., Woolley, K. E., & Morris, R. (2024) · ORCA Online Research @Cardiff (Cardiff University)
Estatinas- passado, presente e futuro na terapêutica
Campaniço, L. (2018) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Programa para la detección de hipercolesterolemia familiar en la provincia de Huelva
Gutiérrez-Cortizo, E. N. (2021) · Repositorio Institucional de la Universidad de Huelva (Universidad de Huelva)
The use of meta-analyzes and other integration methods in clinical 'outcomes' evaluation
Kohout, P., & Pavel, K. (2017) · Czech Technical University Digital Library (Czech Technical University in Prague)
Metodi statistici per la valutazione di costo-efficacia in HTA
Fornari, C. (2012) · BOA (University of Milano-Bicocca)
Borowski, S. C., Edwards, E. R., Geraci, J. C., Gildea, S. M., Hwang, I. H., Kennedy, C. J., Liu, H. Y., Luedtke, A. R., Sampson, N. A., Benedek, D. M., et al. (2026) · npj Mental Health Research · doi:10.1038/s44184-026-00192-8
Handels, R. L. H., Hoevenaar‐Blom, M. P., Song, M., Brayne, C., van Charante, E. P. M., Matthews, F. E., Xu, J., Jönsson, L., Coley, N., Brooks, R. L., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100526
Skeletal muscle toxicity and statins : role of mitochondrial adaptations
Singh, F. (2016) · theses.fr (ABES) · doi:10.70675/362675f3z0a19z46f5z977az009dcec8ed40
Deo, S. V., Ciminata, G., Mahalwar, G., Salerno, P. R. V. D. O., McAllister, D., Elgudin, Y. E., Orkaby, A. R., Virani, S., Fremes, S. E., Rajagopalan, S., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.124.040272
Price, P. U., Paganelli, M. O., Campos, M. S. D. A., & Pereira, L. R. L. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101646
Vivoda, K., Koh, H. J. W., Abebe, T. B., Rodda, S. E., Bain, C., & Ademi, Z. (2026) · PharmacoEconomics · doi:10.1007/s40273-026-01631-2
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.